1. Villiers EM de. Cross-roads in the classification of papillomaviruses. Virology 2013; 445(1–2): 2–10, doi: 10.1016/j.virol.2013.04.023.
2.
Forman D, Martel C de, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30(Suppl. 5): F12–F23, doi: 10.1016/j.vaccine.2012.07.055.
3.
Taylor CA, Keller ML, Egan JJ. Advice from affected persons about living with human papillomavirus infection. J Nurs Sch 1997; 29(1): 27–32, doi: 10.1111/j.1547-5069.1997.tb01136.x.
4.
Syrjänen S. Current concepts on human papillomavirus infections in children. APMIS 2010; 118(6–7): 494–509, doi: 10.1111/j.1600-0463.2010.02620.x.
5.
Merckx M, Liesbeth WV, Arbyn M, et al. Transmission of carcinogenic human papillomavirus types from mother to child: a meta-analysis of published studies. Eur J Cancer Prev 2013; 22(3): 277–285, doi: 10.1097/CEJ.0b013e3283592c46.
6.
Couto E, Sæterdal I, Juvet LK, et al. HPV catch-up vaccination of young women: a systematic review and meta-analysis. BMC Public Health 2014; 14: 867, doi: 10.1186/1471-2458-14-867.
7.
Serrano B, de Sanjosé S, Tous S, et al. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer 1990; 51(13): 1732–1741, doi: 10.1016/j.ejca.2015.06.001.
8.
Graham SV. The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review. Clin Sci (Lond) 2017; 131(17): 2201–2221, doi: 10.1042/CS20160786.
9.
Doorbar J, Egawa N, Griffin H, et al. Human papillomavirus molecular biology and disease association. Rev Med Virol 2015; 25: 2–23, doi: 10.1002/rmv.1822.
10.
Schiffman M, Doorbar J, Wentzensen N, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers 2016; 2: 16086, doi: 10.1038/nrdp.2016.86.
11.
Ren S, Gaykalova DA, Guo T, et al. HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers. Oncogene 2020; 39: 6327–6339, doi: 10.1038/s41388-020-01431-8.
12.
Saraiya M, Unger ER, Thompson TD, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst 2015; 107(6): djv086, doi: 10.1093/jnci/djv086.
13.
World Health Organization, National Agency for Research. Cancer Today [cited 05.11.2021]. Available from URL: https://gco.iarc.fr/today/.
14.
Didkowska J, Wojciechowska U. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy [cited 05.11.2021]. Available from URL: http://onkologia.org.pl/k/epidemiologia/ (in Polish).
15.
Gross G. Differenzialdiagnostik Anogenitaler Condylomata Acuminata. Indikation für die histopathologische Untersuchung. Hautarzt 2009; 6, doi: 10.1007/s00105-008-1694-9 (in German).
16.
Philp L, Jembere N, Wang L, et al. Pap tests in the diagnosis of cervical cancer: help or hinder? Gynecol Oncol 2018; 150(1): 61–66, doi: 10.1016/j.ygyno.2018.05.019.
17.
Saslow D, Solomon D, Lawson H, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012; 62(3): 147–172, doi: 10.3322/caac.21139.
18.
Nasierowska-Guttmejer A, Kędzia W, Rokita W, et al. Polish recommendations regarding diagnostics and treatment of cervical squamous intraepithelial lesions according to the CAP/ASCCP guidelines. Ginekol Pol 2016; 87(9): 670–676, doi: 10.5603/GP.2016.0066.
19.
Moscicki AB, Darragh TM, Berry-Lawhorn JM, et al. Screening for anal cancer in women. J Low Genit Tract Dis 2015; 19(3 Suppl. 1): S27–S42, doi: 10.1097/LGT.0000000000000117.
20.
Yu YB, Wang YH, Yang XC, et al. The relationship between human papillomavirus and penile cancer over the past decade: a systematic review and meta-analysis. Asian J Androl 2019; 21(4): 375–380, doi: 10.4103/aja.aja_39_19.
21.
Balaji R, MacCosham A, Williams K, et al. Directionality of genital human papillomavirus infection transmission within heterosexual couples: A systematic review and meta-analysis. J Infect Dis 2020; 222(11): 1928–1937, doi: 10.1093/infdis/jiaa302.
22.
Isaguliants M, Krasnyak S, Smirnova O, et al. Genetic instability and anti-HPV immune response as drivers of infertility associated with HPV infection. Infect Agent Cancer 2021; 16(1): 29, doi: 10.1186/s13027-021-00368-1.
23.
Tyring SK. Effects on HPV-induced enzymes involved in inflammatory mediator generation. J Clin Aesthet Dermatol 2012; 5(1): 19–26.
24.
Méndez‐Flores S, Esquivel‐Pedraza L, Hernández‐Salazar A, et al. Focal epithelial hyperplasia in adult patients with HIV infection: clearance with topical imiquimod. Skinmed 2016; 14: 395–397.
25.
Wieland U, Kreuter A. HPV-induzierte anale Läsionen. Hautarzt 2015; 66(6): 439–445, doi: 10.1007/s00105-015-3630-0 (in German).
26.
U.S. Food and Drug Administration. Human papillomavirus bivalent vaccine [cited 22.08.2021]. Available from URL: https://www.fda.gov/vaccines-blood-biologics/approved-products/cervarix.
27.
Sanjose de S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048–1056, doi: 10.1016/S1470-2045(10)70230-8.
28.
U.S. Food and Drug Administration. Human papillomavirus quadrivalent vaccine [cited 22.08.2021]. Available from URL: https://www.fda.gov/vaccines-blood-biologics/approved-products/gardasil.
29.
U.S. Food and Drug Administration. Human papillomavirus 9-valent vaccine [cited 22.08.2021]. Available from URL: https://www.fda.gov/vaccines-blood-biologics/approved-products/gardasil-9.
30.
UNICEF Supply Division. Human papillomavirus vaccine supply and demad update [cited 22.08.2021]. Available from URL: https://www.unicef.org/supply/media/5416/file/Human-Papillomavirus-Vaccine-Market-Update-June2018.pdf.
31.
Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health 2016; e453–e463, doi: 10.1016/S2214-109X(16)30099-7.
32.
United Nations International Children’s Emergency Fund. Szczepienia zalecane wśród dzieci i młodzieży [cited 20.08.2021]. Available from URL: https://dzieciwpolsce.pl/statystyka/37/szczepienia-zalecane-wsrod-/tabele/glowny (in Polish).
33.
Ministerstwo Zdrowia. Program wieloletni pn. Narodowa Strategia Onkologiczna na lata 2020–2030 [cited 22.08.2021]. Available from URL: https://www.onkonet.pl/pdf/nso_06_02_2020.pdf (in Polish).
34.
Human papillomavirus vaccines. WHO position paper, May 2017. Weekly Epidemiol Rec 2017; 92: 241–268.
35.
Arana JE, Harrington T, Cano M, et al. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009–2015. Vaccine 2018; 36(13): 1781–1788, doi: 10.1016/j.vaccine.2018.02.034.
36.
Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine 2011; 29: 8279–8284, doi: 10.1016/j.vaccine.2011.08.106.
37.
Lei J, Ploner A, Elfström KM, et al. HPV vaccination and the risk of invasive cervical cancer. NEJM 2020; 383(14): 1340–1348, doi: 10.1056/NEJMoa1917338.
38.
Palmer T, Wallace L, Pollock KG, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12–13 in Scotland: retrospective population study. BMJ 2019; 365: l1161, doi: 10.1136/bmj.l1161.
39.
Ganczak M, Owsianka B, Korzeń M. Factors that predict parental willingness to have their children vaccinated against HPV in a country with low HPV vaccination coverage. Int J Environ Res Public Health 2018; 15(4): 645, doi: 10.3390/ijerph15040645.
40.
Hastings TJ, Hohmann LA, McFarland SJ, et al. Pharmacists’ attitudes and perceived barriers to Human Papillomavirus (HPV) vaccination services. Pharmacy (Basel) 2017; 5(3): 45, doi: 10.3390/pharmacy5030045.
41.
Loke AY, Chan A, Wong YT. Facilitators and barriers to the acceptance of human papillomavirus (HPV) vaccination among adolescent girls: a comparison between mothers and their adolescent daughters in Hong Kong. BMC Res Notes 2017; 10(1): 390, doi: 10.1186/s13104-017-2734-2.
42.
Borena W, Luckner-Hornischer A, Katzgraber F, et al. Factors affecting HPV vaccine acceptance in west Austria: Do we need to revise the current immunization scheme? Papillomavirus Pes 2017; 2: 173–177, doi: 10.1016/j.pvr.2016.10.001.
43.
Strategic Advisory Group of Experts on Immunization. World Health Organization. Report of the SAGE Working Group on Vaccine Hesitancy. Geneva, Switz: WHO 2014 [cited 22.08.2021]. Available from URL: www.who.int.myaccess.library.utoronto.ca/immunization/sage/meetings/2014/october/1_Report_WORKING_GROUP_vaccine_hesitancy_final.pdf.
44.
Victory M, Do T, Kuo YF, et al. Parental knowledge gaps and barriers for children receiving human papillomavirus vaccine in the Rio Grande Valley of Texas. Hum Vaccin Immunother 2019; 15(7–8): 1678–1687, doi: 10.1080/21645515.2019.1628551.
45.
Sypień P, Marek W, Zielonka TM. Awareness and attitude of pediatricians towards human papilloma virus vaccinations in Poland. J Pediatr Child Health Care 2020; 5(1): 1031.
46.
McRee AL, Gilkey MB, Dempsey AF. HPV vaccine hesitancy: findings from a statewide survey of health care providers. J Pediatr Health Care 2014; 28(6): 541–549, doi: 10.1016/j.pedhc.2014.05.003.
47.
[National Institute of Public Health – National Institute of Hygiene. Increasing problem with vaccine hesitancy among Polish parents] [cited 22.05.2020]. Available from URL: http://szczepienia.pzh.gov.pl/en/stories/increasing-vaccine-hesitancy/ (in Polish).
